OncoMatch/Clinical Trials/NCT06997081
ERd Combination Treatment in Newly Diagnosed Multiple Myeloma
Is NCT06997081 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Lenalidomide and Dexamethasone for multiple myeloma.
Treatment: Lenalidomide · Dexamethasone · Elranatamab — The purpose of this study is to determine the effects that Elranatamab in combination with Lenalidomide and Dexamethasone has on participants that have been newly diagnosed with Multiple Myeloma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: multiple myeloma therapy
Exception: ≤1 cycle of prior treatment allowed; see protocol for permitted exceptions
Participants receiving >1 cycle of prior treatment or concurrent systemic treatment for MM with the following exceptions: ... Patients with measurable disease who received up to one cycle of any therapy within 60 days with a washout period of 2 weeks from last dose (on a trial or outside a trial) are eligible
Cannot have received: carfilzomib (carfilzomib)
Exception: only for patients with Smoldering Multiple Myeloma (SMM)
Patients with Smoldering Multiple Myeloma (SMM) previously treated with carfilzomib are excluded
Lab requirements
Blood counts
ANC >1.0 K/μL (0.5-1.0 K/μL allowed at investigator discretion if chronic/ethnic neutropenia and no complications); Platelet count >75 K/μL; Hemoglobin >8 g/dL (transfusions allowed if anemia not due to myeloma)
Kidney function
GFR ≥30 mL/min (MDRD or other accepted method) or creatinine clearance measured by 24-hour urine collection
Liver function
Total bilirubin <1.5 X ULN (isolated total bilirubin ≥1.5 X ULN with conjugated [direct] bilirubin <1.5 X ULN is allowed for Gilbert's syndrome); AST/ALT ≤2.5 X ULN
Participants must have adequate organ and marrow function ≤45 days as defined below: ANC >1.0 K cells/μL; Platelet count >75 K cells/μL; Hemoglobin >8 g/dL; Total bilirubin <1.5 X ULN; AST/ALT ≤2.5 X ULN; GFR ≥30 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Miami · Miami, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify